在类风湿关节炎患者日常实践中,初始糖皮质激素桥接治疗是否与病程后期使用糖皮质激素和生物制剂DMARDs相关?一项真实世界数据分析
本研究基于莱顿大学医学中心新诊断类风湿关节炎患者的电子健康记录数据,比较初始治疗即启用糖皮质激素(iGC组)与未启用者(niGC组)在病程后期使用糖皮质激素和生物制剂DMARDs的概率。结果显示iGC组DAS28下降更快,后期(再)启用糖皮质激素的风险更高(aHR 1.37,95%CI 1.09;1.73),而启用bDMARD的风险无显著增加。
要点
- 932例新诊断RA患者中465例(50%)初始治疗即使用糖皮质激素。
- iGC组随访期间42%启用第二疗程糖皮质激素、17%启用bDMARD,niGC组分别为34%和13%。
- iGC组后期(再)启用糖皮质激素的风险更高(aHR 1.37,95%CI 1.09;1.73),bDMARD启用风险无显著差异。
核心结论
- 在新诊断RA的日常实践队列中,iGC组较niGC组DAS28下降更快,且后期启用糖皮质激素的概率增加,而bDMARD使用概率未显著增加。
研究设计与样本
- 使用莱顿大学医学中心新诊断RA患者的电子健康记录数据,比较初始治疗启用糖皮质激素(iGC组)与未启用者(niGC组),并进行多变量校正以控制适应证混杂。
主要发现
- 932例新诊断RA患者中465例(50%)初始治疗使用糖皮质激素。
- iGC组较niGC组年龄更大、女性更少、基线疾病活动度更高,且前6个月DAS28下降更快。
- 随访期间iGC组42%启用第二疗程糖皮质激素、17%启用bDMARD,niGC组分别为34%和13%。
- 两个时间段内后期启用bDMARD的风险在两组间无显著差异(0.34,95%CI 0.09;1.21;1.48,95%CI 0.98;2.22)。
- iGC组后期(再)启用糖皮质激素的风险更高(aHR 1.37,95%CI 1.09;1.73)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate if initially starting glucocorticoid (GC) bridging leads to a higher probability of long-term GC and biological (b)DMARD use in rheumatoid arthritis (RA)-patients. METHODS: Electronical health records data from newly diagnosed RA-patients from the Leiden University Medical Center were used. Patients who started GC as part of initial treatment (iGC group) and who did not (niGC group) were compared in terms of GC and bDMARD use later in the disease course. Multivariable adjustment was performed to account for confounding by indication. RESULTS: 465/932 newly diagnosed RA-patients (50 %) were treated with GC as initial treatment step. Patients in the iGC group were older, included fewer females, had a higher disease activity at baseline compared to the niGC group plus a more rapid decrease in DAS28 in the first 6 months. During follow-up, 42 % of the iGC group started a second course of GC and 17 % started a bDMARD, compared to 34 % and 13 % In the niGC group. The hazard to start a bDMARD later in the disease course was not significantly different between the two groups in two time periods (0.34 95 %CI(0.09;1.21) resp. 1.48 95 %CI (0.98;2.22)), but the hazard to (re)start GC later on was higher for the iGC group (aHR 1.37 95 %CI(1.09;1.73)). CONCLUSION: In this daily practice cohort of newly diagnosed RA patients, patients in the iGC group had a more rapid DAS28 decrease and an increased probability of starting GC later on compared to the niGC group. The probability of bDMARD use was not significantly increased.
引用
- van Ouwerkerk L, Bergstra SA, Maarseveen TD, et al. Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis. Semin Arthritis Rheum. 2023. PMID: 37992515. doi:10.1016/j.semarthrit.2023.152305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。